The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma.
The approval is for the use of olaratumab in combination with doxorubicin in patients with sarcoma that cannot be cured by radiation therapy or surgery and for whom anthracycline-based chemotherapy would be an appropriate treatment.
from Cancer via ola Kala on Inoreader http://ift.tt/2fevxf1
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου